Eur J Obstet Gynecol Reprod Biol. 2014 Jun;177:121-5. doi: 10.1016/j.ejogrb.2014.03.016. Epub 2014 Apr 2.
Tuten A1, Sahmay S2, Oncul M2, Acikgoz AS2, Imamoglu M2, Gurleyen HC2, Senturk ML2.
1Department of Obstetrics and Gynecology, Cerrahpasa School of Medicine, Istanbul University, Istanbul, Turkey. Electronic address: firstname.lastname@example.orgDepartment of Obstetrics and Gynecology, Cerrahpasa School of Medicine, Istanbul University, Istanbul, Turkey.
Eur J Obstet Gynecol Reprod Biol
OBJECTIVE: To investigate the diagnostic potential of anti-Müllerian hormone (AMH) in the differential diagnosis of various hyperandrogenemic conditions.STUDY DESIGN: Among 2241 consecutive women of reproductive age who were seen at a tertiary care university hospital with complaints of acne, hirsutism, androgenetic alopecia, and menstrual dysfunction (oligomenorrhea and/or amenorrhea), 107 patients with serum 17a-hydroxyprogesterone (17a-OHP) levels higher than 2ng/ml were recruited for this study. An ACTH stimulation test was performed, and basal serum hormonal parameters and AMH levels were measured for all patients.RESULTS: 25 patients were diagnosed with late-onset congenital adrenal hyperplasia (LOCAH), and 59 patients with polycystic ovary syndrome (PCOS) had significantly higher serum AMH levels than all other groups.CONCLUSION: Among hyperandrogenemic patients with serum 17a-OHP levels >2ng/ml, serum AMH levels might be introduced as a marker to be utilized clinically in the differential diagnosis of hyperandrogenemic patients, especially for identifying patients with PCOS.Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
Full Text Source: Elsevier Science
PMID:24768424 | http://www.ncbi.nlm.nih.gov/pubmed/24768424